A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk.

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Karl Mårild, Jonas Söderling, Jordan Axelrad, Jonas Halfvarson, Anders Forss, Karl Michaëlsson, Ola Olén, Jonas F Ludvigsson
{"title":"A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk.","authors":"Karl Mårild, Jonas Söderling, Jordan Axelrad, Jonas Halfvarson, Anders Forss, Karl Michaëlsson, Ola Olén, Jonas F Ludvigsson","doi":"10.1111/apt.18275","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity.</p><p><strong>Aims: </strong>To determine the fracture risk in IBD during periods with and without histological inflammation.</p><p><strong>Methods: </strong>We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990-2016 with longitudinal data on ileo-colorectal biopsies. Fractures were identified by inpatient and hospital-based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio-demographics, comorbidities, IBD duration, IBD-related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.</p><p><strong>Results: </strong>Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29-1.46) fractures per 100 years' follow-up versus 1.31 (95% CI 1.19-1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00-1.26; p = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91-1.36) and ulcerative colitis (1.18; 95% CI 1.02-1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid-naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07-1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87-1.92).</p><p><strong>Conclusions: </strong>Histological inflammation in IBD predicted a small increase in short-term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18275","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity.

Aims: To determine the fracture risk in IBD during periods with and without histological inflammation.

Methods: We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990-2016 with longitudinal data on ileo-colorectal biopsies. Fractures were identified by inpatient and hospital-based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio-demographics, comorbidities, IBD duration, IBD-related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.

Results: Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29-1.46) fractures per 100 years' follow-up versus 1.31 (95% CI 1.19-1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00-1.26; p = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91-1.36) and ulcerative colitis (1.18; 95% CI 1.02-1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid-naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07-1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87-1.92).

Conclusions: Histological inflammation in IBD predicted a small increase in short-term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.

Abstract Image

一项关于炎症性肠病、组织学活动和骨折风险的全国性队列研究。
背景:炎症性肠病(IBD)患者的骨折风险增加。目的:确定IBD患者在有组织学炎症和无组织学炎症期间的骨折风险:我们对 1990-2016 年间全国范围内 54,591 名被诊断为 IBD 患者的队列进行了研究,并获得了回肠直肠活检的纵向数据。骨折是通过住院病人和医院门诊诊断确定的。在对社会人口统计学、合并症、IBD 病程、IBD 相关手术和住院治疗进行调整后,我们得出了组织学炎症(与组织学缓解)记录后 12 个月内骨折的 Cox 回归估计危险比 (HRs)。我们对包括皮质类固醇在内的 IBD 药物治疗进行了敏感性分析调整:组织学炎症和缓解期患者活检时的平均年龄分别为 44.0 岁(SD = 18.3)和 45.5 岁(SD = 17.1)。组织学炎症患者每随访100年会发生1.37(95% CI 1.29-1.46)例骨折,而缓解期患者每随访100年会发生1.31(95% CI 1.19-1.44)例骨折(调整后[a]HR为1.12;95% CI为1.00-1.26;P = 0.04)。克罗恩病(1.11;95% CI 0.91-1.36)和溃疡性结肠炎(1.18;95% CI 1.02-1.36)组织学炎症的 HR 值相似。各年龄组的估计值一致。在考虑皮质类固醇后,任何骨折的总体超额风险仍然很小。在皮质类固醇无效的 IBD 患者中,组织学炎症与组织学缓解相比,骨折风险明显升高(aHR 1.41;95% CI 1.07-1.85)。组织学炎症后髋部骨折的aHR为1.29(95% CI 0.87-1.92):结论:IBD组织学炎症可预测短期骨折风险的小幅增加。减少疾病活动的措施可降低 IBD 患者的骨折风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信